CRA Investigational Product Management 3

Question 1

What is the purpose of a blinded randomization code in investigational product management?

Accepted Answer

To assign subjects to treatment groups while keeping the assignment concealed

Answer

To encrypt electronic safety data submissions to the FDA

Answer

To code adverse events by severity and relatedness

Answer

To organize subject files in the Investigator Site File

Question 2

When a subject discontinues from a clinical trial early, what must happen to any remaining investigational product in their possession?

Accepted Answer

It must be returned to the site and documented in the drug accountability records

Answer

The subject may retain it as compensation for trial participation

Answer

It should be discarded by the subject in household waste

Answer

No action is required once a subject is discontinued

Question 3

What is a 'comparator drug' in the context of a randomized controlled clinical trial?

Accepted Answer

An approved product or placebo used as a reference treatment against the investigational drug

Answer

A drug used to compare pricing across multiple pharmacies

Answer

A secondary investigational drug tested in the same protocol

Answer

A rescue medication used to manage adverse events in subjects

Question 4

Which of the following best describes what a CRA is verifying when conducting an investigational product accountability review?

Accepted Answer

That all IP received, dispensed, on hand, returned, and destroyed is documented and quantities balance

Answer

That the site has adequate staff levels to conduct the trial

Answer

That the IRB approval letter covers the current protocol version

Answer

That all adverse events have been properly graded and reported

Question 5

What is the primary risk when a site fails to maintain adequate temperature monitoring records for investigational product storage?

Accepted Answer

Regulatory findings, protocol deviations, and data integrity concerns that could compromise the trial

Answer

The site may receive fewer subjects in future enrollment waves

Answer

Only an increased monitoring frequency by the sponsor

Answer

No significant risk as long as the product appears visually intact

Question 6

Under ICH E6(R2) GCP guidelines, who must be authorized to access investigational product at a clinical site?

Accepted Answer

Only individuals formally authorized and listed on the site delegation log

Answer

Only the Principal Investigator personally

Answer

All site staff members who have signed a confidentiality agreement

Answer

IRB members may access IP upon written request at any time

Question 7

What must a CRA document after completing an investigational product accountability review during a monitoring visit?

Accepted Answer

All findings, any discrepancies identified, and confirmation that accountability records are complete and accurate

Answer

Only the total number of subjects currently enrolled in the trial

Answer

Only a description of the physical condition of the drug storage area

Answer

The names and credentials of all pharmacy staff present during the review